Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Galecto | Damora Therapeutics

Biotech & Life Sciences · Copenhagen, Denmark · Founded 2011 · IPO 2020 Unicorn

Biotechnology for mutant calreticulin-driven hematologic disorders, formerly known as Galecto

Valuation
$1.71B
Market cap · May/2026
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

33 investors on Galecto | Damora Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 4 investors entered at this stage
Novo Seeds
Sunstone Life Science Ventures
M Ventures
Seed Capital
Series B+ 29 investors entered at this stage
RA Capital Management
Novo Holdings
Fairmount Partners
Cormorant Asset Management
Hadean Ventures
TCGX
Eir Ventures
Lund University
Forbion Capital Partners
Janus Henderson Investors
Venrock
Wellington Management
Bristol-Myers Squibb
Commodore Capital
Seventure Partners
Maverick Ventures
Balyasny Asset Management
Viking Global Investors
Vestal Point Capital
Ysios Capital
Blackstone
Sphera
Perceptive Advisors
Soleus Capital
OrbiMed
Andreessen Horowitz
Canica
BB Biotech
Asymmetry capital management

Global footprint

Where Galecto | Damora Therapeutics has talent and traffic

Workforce by country
🇩🇰 Denmark · Copenhagen HQ
Book a demo for the full country breakdown
Web traffic by country
1.7K monthly visits
across markets
🇺🇸 United States100%
Top 1 markets shown

Market sentiment

What the market is saying about Galecto | Damora Therapeutics

An AI-synthesized read of the highest-engagement posts about Galecto | Damora Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Galecto | Damora Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles